Furthermore, given that other anti-diabetic treatments such as SGLT-2 inhibitors are feared to adversely affect bone health, there is increasing interest in the benefits of GLP-1 analogs for diabetic post-menopausal women (251)
IUPHAR/BPS receptor-family data and published reviews separate these receptor subtypes by nomenclature, genes, transduction pathways, and endogenous ligand relationships [3] [8]
doi: 10.1126/science.aax3768 41
These effects are typically most pronounced when starting therapy or increasing the dose and often diminish as the body adjusts to the medication
In the UK, it is estimated that around 3.5 million people live with osteoporosis, with postmenopausal women and older adults being the most commonly affected groups
Visible improvements can often be noticed within a few weeks of consistent use, though results may vary